Secukinumab


( Last Updated : January 21, 2016)
Generic Name:
Secukinumab
Project Status:
Complete
Therapeutic Area:
Arthritis, psoriatic
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cosentyx
Project Line:
Reimbursement Review
Project Number:
SR0476-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Submission Type:
Initial
Indications:
Arthritis, psoriatic
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation: